News

A Promising New AIDS Drug Highlights The Dangers Of Price Controls
The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
MedTech Dive22m
J&J’s Abiomed recalls heart pump controllers after 3 patients die
Johnson & Johnson’s Abiomed has recalled automated controllers for its Impella heart pumps over a fault linked to three ...
Even as prices drop, it's difficult to keep up with demand for new obesity drugs
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...
BioSpace34m
5 Second-Half Biopharma Milestones To Watch
After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...
Rheumatology Advisor1h
Gamifant Approved in Adults, Children With HLH/MAS in Still Disease
The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.
Nationwide Gummies Recall Update as FDA Issues Highest Risk Warning
Vita Warehouse Corp. recalled more than 40,000 bottles of Vitamin B12 supplements for possible undeclared presence of peanut.
STAT1h
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
STAT1h
Pharmalittle: We’re reading about FDA morale, a U.S.-Swiss trade deal on pharma levies, and more
The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exit ...
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...
Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.